GIMAP2 activators constitute a specialized category of chemical agents that target the GTPase of the immunity-associated protein 2 (GIMAP2), a member of the GTPases of the immunity-associated proteins family. These proteins are part of a larger group of GTPases, which are enzymes that hydrolyze guanosine triphosphate (GTP) to guanosine diphosphate (GDP). GIMAP2, in particular, is believed to play a role in the regulation of apoptosis and cell survival as well as in the maintenance of the immune system's cellular components. The activators of GIMAP2 are chemicals that interact with this protein, promoting its GTPase activity. By increasing the rate at which GIMAP2 converts GTP to GDP, these activators influence the biochemical pathways in which GIMAP2 is involved. The exact mechanisms through which GIMAP2 activators exert their influence on the function of the protein are the subject of ongoing research, but they are understood to interact with the protein's active sites or regulatory domains to induce a conformational change that results in increased activity.
The design and discovery of GIMAP2 activators typically involve high-throughput screening of chemical libraries to identify compounds that enhance GIMAP2 activity, followed by iterative cycles of structure-activity relationship (SAR) studies. These studies aim to refine the potency, selectivity, and stability of the activators by making systematic modifications to their chemical structures. As with other GTPase-targeting agents, the precise interaction between GIMAP2 activators and their target requires detailed understanding of the protein's structure and the dynamics of its active site. Advanced techniques like X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and computational modeling play crucial roles in elucidating these interactions. By piecing together the puzzle of how these activators bind and modulate GIMAP2, chemists can optimize the compounds to achieve desired levels of activity. The discovery and optimization of GIMAP2 activators are thus grounded in the principles of biochemistry and molecular biology, relying on a deep understanding of protein structure and function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA acts as a diacylglycerol analog and activates Protein Kinase C (PKC), which can phosphorylate GIMAP2, leading to its enhanced functional activity within immune cells. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 increases intracellular calcium levels, which can activate calcium-dependent protein kinases that may phosphorylate GIMAP2, resulting in its activation. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin elevates intracellular cyclic AMP (cAMP) levels, which activates PKA. PKA can subsequently phosphorylate GIMAP2, thereby enhancing its activity. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin acts as a calcium ionophore, increasing intracellular calcium concentration, which could lead to the activation of calcium-dependent kinases that phosphorylate GIMAP2. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
8-Bromo-cAMP is a cell-permeable cAMP analog that activates PKA, which might enhance the activity of GIMAP2 through phosphorylation. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a PKC inhibitor. Inhibition of specific PKC isoforms could lead to a compensatory increase in GIMAP2 activity due to reduced competition for shared downstream effectors. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
PGE2 engages the EP2/EP4 receptors, leading to increased cAMP levels and PKA activation, which can enhance GIMAP2 activity through phosphorylation. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a beta-adrenergic agonist that raises cAMP levels and activates PKA, potentially leading to increased phosphorylation and activation of GIMAP2. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
S1P activates sphingosine-1-phosphate receptors, leading to downstream PKC activation, which can then enhance GIMAP2 activity through phosphorylation. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic acid is a potent inhibitor of protein phosphatases PP1 and PP2A, leading to increased phosphorylation levels of proteins, potentially including GIMAP2, thus enhancing its activity. | ||||||